Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Industry News

Qiagen offers AdnaTest for lung, prostate cancers

April 20, 2018—Qiagen launched two liquid biopsy panels to evaluate circulating tumor cells in prostate and lung cancers. The AdnaTest ProstateCancerPanel AR-V7 Kit and AdnaTest LungCancer Kit were introduced at the American Association for Cancer Research annual meeting, April 14–18, in Chicago. The AdnaTest ProstateCancerPanel AR-V7 Kit detects the androgen receptor splice variant 7 in CTCs of prostate tumor origin isolated from blood samples to investigate potential resistance to drugs for advanced prostate cancer. Qiagen is launching the test for

Meridian launches TruBlock Ready

April 19, 2018—Meridian Life Science launched TruBlock Ready, a broad-acting HAMA blocker that is ready to use within a single dilution step. TruBlock Ready employs an active blocking technology that results in higher blocking efficiency than conventional blockers and provides broad coverage against human anti-mouse antibody, rheumatoid factor, and heterophilic antibodies. The blocking effectiveness has been proven in ELISA and lateral flow assay formats. More top news

Sakura launches Tissue-Tek Prisma Plus

April 13, 2018—Sakura Finetek USA launched its Tissue-Tek Prisma Plus Automated Slide Stainer, a second-generation Prisma platform with a throughput of 530 slides per hour. “Like its predecessor, the Tissue-Tek Prisma Automated Slide Stainer, with several thousand units installed worldwide, Tissue-Tek Prisma Plus continues to be the slide stainer of choice for large commercial laboratories and hospitals,” George R. Kennedy, SVP of sales and marketing at Sakura Finetek USA, said in a press release. “We are proud of the performance

Beckman introduces Access Sensitive Estradiol

April 11, 2018—Beckman Coulter Diagnostics announced the launch of its Access Sensitive Estradiol assay in the U.S. and in a majority of markets worldwide. The test is commonly ordered for detecting estradiol levels in women, children, and men. The assay aims to help laboratories deliver more accurate results for patients seeking answers to reproductive health questions. It has a broad measuring range, surpassing clinical decision limits for in vitro fertilization hyper responders. This may allow laboratories to report accurate patient

DiaSorin gets FDA clearance for PCT assay

April 6, 2018—DiaSorin received clearance from the Food and Drug Administration to market the Liaison Brahms PCT II Gen assay for the quantitative determination of procalcitonin. “I am pleased to announce the addition of the Brahms PCT II Gen assay to our growing specialty menu in the U.S. market”, John Walter, president of DiaSorin, said in a statement. “I’m proud of the great collaboration between various DiaSorin groups that allowed for the rapid clearance of the product. In addition to

AdvantEdge acquires PMI

April 5, 2018—AdvantEdge Healthcare Solutions, a medical billing company, has acquired Professional Management Inc., a Baltimore-based medical …

FDA authorizes DexcomG6 CGM system

March 30, 2018—The FDA has granted a de novo request to Dexcom for its Dexcom G6 integrated continuous glucose monitoring system for determining blood glucose levels for people with diabetes ages two and up. This is the first type of CGM system permitted by the agency to be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters, or other electronic devices used

Roche launches digital pathology slide scanner

March 28, 2018—Roche launched the Ventana DP 200 high-speed slide scanner for digital pathology. The scanner features a tray-based design that enables no-touch slide processing for reduced workflow and a scan speed of less than 49 seconds for a 15-by-15 millimeter scan area. It is Digital Imaging and Communications in Medicine (DICOM) standard compatible and integrates with image management servers, including Ventana Virtuoso software. “The Ventana DP 200 slide scanner provides the pathology lab with image quality and ease of

CAP TODAY webinar on BRCA mutation testing

March 26, 2018—CAP TODAY is hosting a webinar titled “Developing Perspectives on BRCA Testing: New Horizons for Breast Cancer” on Thursday, March 29, 1:30 PM ET. Tabetha Sundin, PhD, HCLD(ABB), MB(ASCP)CM, and Leigha Senter-Jamieson, MS, LGC, will discuss the rationale for BRCA mutation testing in breast cancer, the key highlights of the BRCA testing and interpretation process, and reconsidering multidisciplinary team roles and responsibilities to streamline the testing experience. This hourlong webinar will be moderated by CAP TODAY publisher Bob

MARKETPLACE

TRENDING